🇺🇸 US Stock Screener ← Switch market ★ Elite Club ⚡ HerAI

Labcorp Holdings Inc. LH SPX

Healthcare · Diagnostics & Research · United States
https://www.labcorp.com
Company Profile ↓
$275.68
+11.53% 1Y
Mkt Cap$22.61B
P/E24.42
P/B2.51
Div. Yield1.08%
52W High$288.63
52W Low$240.50
Book Value$106.06
EPS (TTM)$11.29

Company Overview

Labcorp Holdings Inc. provides laboratory services. It operates through two segments, Diagnostics Laboratories and Biopharma Laboratory Services. The company offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, PAP tests, hemoglobin A1C, PSA, tests for sexually transmitted diseases, vitamin D testing, microbiology cultures and procedures, and alcohol and other substance abuse tests. It also provides specialty testing services comprising gene-based and esoteric testing; advanced tests target specific diseases; services related to anatomic pathology/oncology, cardiovascular disease, coagulation, diagnostic genetics, endocrinology, infectious disease, women's health, pharmacogenetics, parentage and donor testing, occupational testing services, medical drug monitoring services, chronic disease programs, and kidney stone prevention tests; and health and wellness services to employers and managed care organizations. In addition, the company offers digital pathology solutions, a pathology platforms that support the digitization, centralized review, and sharing of pathology slides; provider and payer digital platforms, an online applications for providers, MCOs, and ACOs; online and mobile applications that enable patients to check offerings, schedule PSC visits, check-in upon PSC arrival, complete documentation, access tests and test results, and manage their accounts; and Generative AI-enabled Test Selection, a generative AI-enabled tool. It serves clients, third party, medicare/medicaid, patients, pharmaceutical, biotechnology, medical device, diagnostic companies, and CROs. The company has a strategic collaboration with the Children's Hospital of Philadelphia to accelerate the discovery, development, and availability of pediatric diagnostics. It also has a collaboration with Alliance for Clinical Trials in Oncology to advance national clinical trial for patients diagnosed with colorectal cancer. The company was founded in 1995 and is headquartered in Burlington, North Carolina.

Why Investors Should Care

Reasonable Valuation

Trades at a P/E of 24.4, below the sector median of 25.4.

Positive Free Cash Flow

Generates positive free cash flow, funding growth and shareholder returns internally.

Recent Developments

  • Dec 2025 Revenue of $13.95B (+7.2% YoY); net profit $876.50M.
  • Trailing 12 Months Year-on-year growth — revenue +5.8%, earnings +32.9%.
  • 5-Year Trend Long-term compounding — revenue CAGR 7.1%, profit CAGR 3.4%.

Growth & Price Performance

Compounded Sales Growth

5 Years:7.09%
1 Year:5.80%

Compounded Profit Growth

5 Years:3.44%
1 Year:32.90%

Stock Price Performance

1 Year:+11.53%
6 Months:+10.06%
3 Months:+4.64%
1 Month:+3.92%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bullish
52-Week Range 73% of range
$240.50 $288.63
Trend Signals
  • Price vs 50-DMAAbove
  • Price vs 200-DMAAbove
  • RSI (14)55.65 · Neutral
Price Performance
1M+3.92%
3M+4.64%
6M+10.06%
1Y+11.53%
Valuation vs Sector

P/E of 24.42 is below the sector median of 25.41 — relatively cheaper than peers.

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • Generates positive free cash flow.

CONS

  • In a downtrend (50-DMA below 200-DMA).

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
24.42
Industry PE
25.41
Forward P/E
14.18
PEG Ratio
1.13
Book Value
$106.06
Price to Book
2.51
P/S
1.54
EV/EBITDA
12.50
Dividend Yield
1.08%

Growth (CAGR)

Revenue 5Y
7.09%
Profit 5Y
3.44%
Revenue (YoY)
5.80%
Earnings (YoY)
32.90%

Profitability & Returns

ROCE
8.89%
ROE
11.05%
ROA
5.31%
Profit Margin
6.66%
Op Margin
10.95%
Gross Margin
28.83%
EPS (Latest Qtr)
$3.35
EPS (TTM)
$11.29

Balance Sheet & Liquidity

Debt/Equity
0.83
Quick Ratio
1.30
Current Ratio
1.73
Debt
$7.29B
Total Assets
$19.09B
Current Assets
-
Working Capital
-

Ownership

Promoter Holding
0.35%
Chg in Prom Hold
-
FII / Inst Holding
101.01%
Chg in FII Hold
-0.26%

Financial Snapshot

Enterprise Value
$22.61B
Total Revenue (TTM)
$14.14B
EBITDA
$2.25B
Free Cash Flow
$1.14B
Operating Cash Flow
$1.81B
Shares Outstanding
82.00M
Gross Margin
28.83%
Payout Ratio
25.51%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP $P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 LH Labcorp Holdings Inc. SPX 275.68 24.42 $22.61B 1.08% 8.89% 11.05% 7.09% 3.44%
2 LLY Eli Lilly and Company SPX 1,152.54 41.02 $1.03T 0.61% - 107.46% 7.20% 11.41%
3 JNJ Johnson & Johnson SPX 253.85 29.45 $611.07B 2.23% 14.88% 26.42% 2.43% 4.76%
4 ABBV AbbVie Inc. SPX 244.78 119.40 $432.48B 3.04% 10.47% -129.24% 1.75% -29.06%
5 UNH UnitedHealth Group Incorporated SPX 425.19 32.02 $386.13B 2.27% 9.74% 12.18% 10.40% 5.43%
6 MRK Merck & Co., Inc. SPX 120.78 34.02 $298.31B 2.86% - 18.94% 5.64% 10.01%
7 AZN AstraZeneca PLC NDX 164.50 24.81 $255.12B 1.77% 15.97% 23.48% 9.82% 45.96%
8 TMO Thermo Fisher Scientific Inc. SPX 534.07 29.33 $198.47B 0.40% 8.14% 13.52% 8.81% 12.95%
9 AMGN Amgen Inc. NDXSPX 355.25 24.69 $191.73B 2.84% 18.02% 101.32% 11.77% 5.58%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric Dec 2014Mar 2015Jun 2015Sep 2015Dec 2015Mar 2016Jun 2016Sep 2016Dec 2016Mar 2017Jun 2017Sep 2017Dec 2017Mar 2018Jun 2018Sep 2018Dec 2018Mar 2019Jun 2019Sep 2019Dec 2019Mar 2020Jun 2020Sep 2020Mar 2021Jun 2021Sep 2021Mar 2022Jun 2022Sep 2022Mar 2023Jun 2023Sep 2023Mar 2024Jun 2024Sep 2024Mar 2025Jun 2025Sep 2025Mar 2026
Revenue -1.79B2.27B2.32B-9.64B2.43B2.41B-2.41B2.53B2.62B2.74B2.85B2.87B2.83B2.79B2.79B2.88B2.93B2.95B2.82B2.77B3.90B4.16B3.84B4.06B3.90B2.92B2.87B3.04B3.03B3.06B3.18B3.22B3.28B3.35B3.53B3.56B3.54B
Gross Profit 546.50M625.10M772.60M764.90M740.70M777.30M826.80M788.40M788.00M712.50M778.00M784.20M817.10M779.00M835.10M789.90M772.40M789.70M824.80M817.30M820.70M728.00M760.50M1.56B1.60B1.26B1.39B1.23B942.50M886.20M850.10M842.20M851.20M897.30M926.40M904.40M948.00M1.05B1.03B1.01B
Operating Income -132.40M323.30M308.10M-299.50M365.50M324.00M-318.10M329.80M326.70M330.60M305.40M369.20M343.40M307.70M318.20M335.70M339.90M336.40M-192.60M297.70M1.05B1.06B704.10M766.90M687.90M428.80M374.00M329.80M266.30M252.30M321.30M294.80M254.10M326.00M394.50M396.60M380.80M
Net Income 119.60M3.00M169.90M154.70M110.00M164.10M204.10M179.50M184.40M183.00M184.80M171.50M687.80M173.20M233.80M318.80M157.90M185.60M190.40M-317.20M227.10M-317.20M231.60M703.40M769.60M467.40M587.30M491.60M358.60M352.80M212.90M188.90M183.30M228.00M205.30M169.30M212.80M237.90M261.10M277.80M
Diluted EPS 1.370.041.661.511.071.581.961.711.751.751.781.656.631.672.273.101.561.861.932.252.32-3.272.377.177.824.766.055.233.873.902.392.122.112.692.432.002.522.843.123.35

Profit & Loss (Annual)

Figures in USD.

Metric Dec 2007Dec 2008Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue 4.07B4.51B4.69B5.00B5.54B5.67B5.81B6.01B8.68B9.55B10.31B11.33B11.55B13.98B13.14B11.86B12.16B13.01B13.95B
Gross Profit 1.69B1.87B1.97B2.10B2.27B2.25B2.22B2.20B2.90B2.85B3.09B3.18B3.25B4.95B4.99B3.71B3.36B3.62B4.01B
Operating Income 777.00M842.90M935.90M978.80M948.40M1.02B990.90M910.40M996.80M1.27B1.31B1.33B1.33B2.45B3.05B1.44B725.60M1.09B1.38B
Net Income 476.80M464.50M543.30M558.20M519.70M583.10M573.80M511.20M437.60M711.80M1.23B883.70M823.80M1.56B2.38B1.28B418.00M746.00M876.50M
Diluted EPS 3.934.164.985.295.115.996.255.914.356.8211.818.618.3515.8824.3913.974.778.8410.46

Balance Sheet (Annual)

Figures in USD.

Metric Dec 2006Dec 2007Dec 2008Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Total Assets --4.67B4.84B6.19B6.11B6.79B6.97B7.30B14.10B14.25B16.67B16.19B18.05B20.07B20.39B20.16B16.73B18.38B18.39B
Total Equity 1.98B1.73B1.69B2.11B2.47B2.50B4.95B2.49B2.82B4.95B5.52B6.80B7.05B7.64B9.44B10.27B10.10B7.88B8.05B8.62B
Cash & Equivalents 51.50M56.40M219.70M148.50M159.30M159.30M404.00M404.00M580.00M716.40M433.60M316.60M426.80M337.50M1.32B1.47B320.60M536.80M1.52B532.30M
Long Term Debt --1.60B977.20M1.83B2.09B2.17B2.89B2.68B5.94B5.30B6.34B5.99B5.79B5.42B5.42B5.04B4.05B5.33B5.08B
Total Liabilities --2.86B2.73B3.70B3.59B4.06B4.46B4.46B9.14B8.73B9.85B9.19B10.46B10.61B10.09B10.04B8.83B10.31B9.76B
Current Liabilities --546.90M1.02B1.12B732.60M1.03B735.70M976.30M1.70B1.83B2.19B1.88B2.66B3.08B2.78B3.08B3.23B3.33B2.82B

Cash Flows (Annual)

Figures in USD.

Metric Dec 2007Dec 2008Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Operating Cash Flow 709.70M780.90M862.40M883.60M855.60M841.40M818.70M739.00M982.40M1.20B1.50B1.31B1.44B2.14B3.11B1.96B1.33B1.59B1.64B
Investing Cash Flow -341.50M-396.00M-334.00M-1.32B-280.30M-534.20M-359.60M-350.10M-3.99B-795.70M-2.23B206.70M-1.28B-643.20M-884.60M-1.65B-1.17B-1.37B-1.19B
Financing Cash Flow -363.70M-218.50M-600.90M515.30M-645.00M-800.00K-518.30M-200.60M3.18B-671.00M593.20M-1.39B-252.70M-517.40M-2.07B-1.32B-59.30M779.90M-1.46B
Capital Expenditure -142.60M-156.70M-114.70M-126.10M-145.70M-173.80M-202.20M-203.50M-255.80M-278.90M-312.90M-379.80M-400.20M-381.70M-421.50M-429.30M-453.60M-489.90M-434.50M
Free Cash Flow 567.10M624.20M747.70M757.50M709.90M667.60M616.50M535.50M726.60M918.20M1.19B925.60M1.04B1.75B2.69B1.53B874.10M1.10B1.21B
Share Buybacks 921.20M333.60M273.00M338.10M643.90M516.50M1.02B269.00M043.90M338.10M700.00M450.00M100.00M1.67B1.10B1.00B250.10M450.00M
Dividends Paid ---------------195.20M254.00M243.10M240.70M

Ratios (Annual)

Figures in %.

Metric Dec 2007Dec 2008Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Gross Margin % 41.6%41.6%42.0%41.9%41.0%39.7%38.3%36.6%33.4%29.9%30.0%28.0%28.1%35.4%38.0%31.3%27.7%27.9%28.8%
Operating Margin % 19.1%18.7%19.9%19.6%17.1%18.0%17.1%15.1%11.5%13.3%12.7%11.7%11.5%17.5%23.2%12.1%6.0%8.4%9.9%
Net Margin % 11.7%10.3%11.6%11.2%9.4%10.3%9.9%8.5%5.0%7.5%11.9%7.8%7.1%11.1%18.1%10.8%3.4%5.7%6.3%
ROE % 27.6%27.5%25.8%22.6%20.8%11.8%23.0%18.1%8.8%12.9%18.0%12.5%10.8%16.5%23.1%12.7%5.3%9.3%10.2%
ROCE % -20.4%24.5%19.3%17.6%17.7%15.9%14.4%8.0%10.2%9.0%9.3%8.6%14.4%17.3%8.4%5.4%7.2%8.9%

Shareholding Pattern

Insiders
0.35%
Institutions
101.01%
Public Float
101.37%

Top Institutional Holders

#Holder% HeldSharesValue
1 Blackrock Inc. 7.86% 6.44M $1.84B
2 Vanguard Capital Management LLC 6.56% 5.38M $1.53B
3 Victory Capital Management Inc. 5.64% 4.63M $1.32B
4 State Street Corporation 4.71% 3.86M $1.10B
5 Vanguard Portfolio Management LLC 4.49% 3.68M $1.05B
6 Boston Partners 2.89% 2.37M $676.08M
7 Allspring Global Investments Holdings, LLC 2.72% 2.23M $635.45M
8 Geode Capital Management, LLC 2.67% 2.19M $623.89M
9 Select Equity Group LP 2.65% 2.17M $620.71M
10 JPMORGAN CHASE & CO 1.87% 1.53M $437.45M

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for LH

Google News hu, 25 Jun 2026

3 Reasons LH is Risky and 1 Stock to Buy Instead - Yahoo Finance

<a href="https://news.google.com/rss/articles/CBMijgFBVV95cUxPSU5CQTFSdURoNnlnOUVzUFhmQnpmRHNFWlBJeTBMMHE2c0huSnMwS1hBa3BySVpCZ3hCOTlQMnNXYUVYdkMzNXBQdnV5UGkxTkRxMkZTWlM5elpWMWo3clRTSG5saXRjQ0JiTDZTNkNGZzBIM0hNR0RSRnF6WWh6aVZHZzN2cTJIOXkwZW…

Google News hu, 09 Jul 2026

Labcorp sets 72-cent dividend for Sept. 11 payout - Stock Titan

<a href="https://news.google.com/rss/articles/CBMihgFBVV95cUxPLUZyWXlzM2NybDhOeTNoMFdjMGYyR3FISV9UNlFFZk1nNjJ0bXNzb3JOOFZjS3hDa3JucWFXUzctRXYyTUtDTDQ5YVQ4Z3Z5SGk2ZWVSY0RiZk1tQkxiSlp5d1QwOThyQXNBdHp1Q01kNEpIM3F3NFNIVlIzMjJQSHFZck9CUQ?oc=5" t…

Google News Mon, 06 Jul 2026

Labcorp Holdings Inc. (LH) Stock Analysis: Evaluating an 8.06% Potential Upside Amid Strong Buy Ratings - DirectorsTalk Interviews

<a href="https://news.google.com/rss/articles/CBMi4wFBVV95cUxNX1ZDR0dZUXpfLXFOVExSV0hvM1FQWkJ6bkZVRWo4RzVNS0NDLUwyTjNkWFM2bklDY0pPcGt3TkpmX29oTFRKS2ZuX2stVWFSanVpaEdwRFVpRzFTREQyUHM1MjdZVUwxZWVpa2ZJd203RmlJbU5CYTdqWFNBcmRPaTZ2eGtsVXYxajM1aW…

Google News ue, 05 May 2026

9-Day Sell-Off Sends Labcorp Stock Down -7.5% - Trefis

<a href="https://news.google.com/rss/articles/CBMipAFBVV95cUxPVUhZRWdCaXFHU1ltYzlRZ1V6eFpZVVAzN0tyM0N1M29WSjBiRlZXd0ppV0VULWRaSG5ad3VvS1VTZ296ZlJaUGNTaDZxNmNPTjlNSGYyRC1NVmNwdzVfdWNsN1hTSW9IRl9DcnFBa01scDBhOER3aDFhQm1DYWdOdEw5RG9sYjRYWHF6Sj…

Google News Fri, 10 Apr 2026

3 Reasons LH is Risky and 1 Stock to Buy Instead - Yahoo Finance

<a href="https://news.google.com/rss/articles/CBMijgFBVV95cUxQMm9YX0JqQjVBVW5NcFZ5NF9GNF9fNDlZeUY5ZW83VzFGNTVtd0xCQ2dSd1lXa1JJQ1lKSWI4NXVVcmhZZjVNOHFrSHI4ZllVSy1SVjQwM3Z6bHJoRDZJbXBJb2lIZGlFSGNVQzc4M0xpcU5MU2dFNmhraWNpOG10b1JwbGx5Yzl3T0F0RX…

Google News Fri, 10 Jul 2026

Labcorp (NYSE: LH) sets $0.72 per-share dividend payable September 11, 2026 - Stock Titan

<a href="https://news.google.com/rss/articles/CBMiqwFBVV95cUxNcjk1UlhXQUxVdGhIbEU5bjlnT1lJZzBQLVB0bnRMY3EwdDJhaUpMZjdXRF9PMlJack8ydGZwWllGTV9wZHZXUXVCX0R0SkhiZTlMUTZUUUQ1OWtKMjVrYnZxdjVLMFoyWWt3eEU3OXdLdkVwc2dMSEtpVkRFRjVhVWlPNVl0emdjRVlkSX…

LH — Frequently Asked Questions

What is the current share price of Labcorp Holdings Inc. (LH)?

As of 2026-07-14 21:23 PDT, Labcorp Holdings Inc. (LH) trades at $275.68 on NYSE. Its 52-week range is $240.50 to $288.63.

What is the market capitalisation of LH?

Labcorp Holdings Inc. (LH) has a market capitalisation of $22.61B on NYSE.

What is the P/E ratio of LH?

LH trades at a trailing price-to-earnings (P/E) ratio of 24.42. The industry average P/E is 25.41. Its price-to-book (P/B) ratio is 2.51.

Does LH pay a dividend?

Labcorp Holdings Inc. (LH) currently offers a dividend yield of 1.08%.

What is the return on equity (ROE) of LH?

LH has a return on equity (ROE) of 11.05%. Its return on capital employed (ROCE) is 8.89%.

Is LH a good stock to buy?

This page provides a data-driven analysis of Labcorp Holdings Inc. (LH), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks
⚙Ad space